After trial failure upon trial failure in Alzheimer's disease will big pharma be prepared to fund a trial using a new approach instead of the amyloid-targeting drugs, that have caused so mu
Eagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and the results have received broadly positive reviews.
